# ONE PRODUCT FOR EVERY PROCEDURE

For years, clinicians have settled for inert resin and ZOE based materials or paid too much for bioactive products. **No longer.** 

NeoMTA 2's unique proprietary gel allows you to mix to a thick putty or a thinner sealer, with performance that puts you on a path to better patient outcomes.

# One product for 13 of your most important procedures:

- ✓ Indirect pulp cap
- ✓ Direct pulp cap
- ✓ Partial pulpotomy
- ✓ Cavity liner
- ✓ Base
- ✓ Pulpotomy

- Perforation repairResorption
- 🗸 Sealing
- ✓ Obturation
- $\checkmark$  Apexification

– Carolyn Primus, PhD

Inventor of White ProRoot®\* MTA<sup>1</sup>, Grev MTA Plus®.

- ✓ Root-end filling
- ✓ Apexogenesis

of their work.

### OUR MOST EFFICIENT WORKING AND SETTING TIMES EVER

NeoMTA 2 is designed for favorable handling properties when mixed to either a sealer or putty consistency. Its working time can be extended if needed by rehydrating the powder with gel – giving you more time to complete your procedure.



## HIGHER RADIOPACITY

NeoMTA 2 vs leading competitors.



All mixed to a putty. RADIOPACITY (mm Al equivalent) Data produced by Avalon Biomed. 2 MTA Angelus<sup>a</sup> is a registered trademark of Angelus Indústria de Productos Odontológicos S/A. 3 Biodentine<sup>a</sup> is a registered trademark of Septodont.

### DIMENSIONALLY STABLE

To ensure a gap-free seal, minimizing opportunity for bacterial infiltration.

#### NeoMTA 2 0.06% expansion

ADA 57 std. ≤1% shrinkage & ≤0.1% expansion


### **NON-STAINING**

- ✓ Won't discolor teeth **EVER**.
- ✓ NaOCI won't cause discoloration.

### IMMEDIATELY WASH-OUT RESISTANT

Stays where you want it so you can efficiently complete the procedure, ensuring bioactive benefit.

With 0% loss of weight, NeoMTA 2 is more stable than leading competitors.



## HIGH pH

To promote osteogenic response.

**RESIN-FREE** For maximum bioactivity.

1 Patented under US Patent No. 7.892,342 owned by DENTSPLY International Inc.

We must give clinicians the

flexibility to work how they want,


without compromising the quality

- Patented under US Patent No. 7,892,342 owned by DENTSPLY Internation
  J Dent. 2014 May;42(5):517-33.
- J Dent. 2014 May;42(5):517-53. A review of the bioactivity of hydraulic calcium silicate cements. Niu LN, Jiao K, Wang TD, Zhang W, Camilleri J, Bergeron BE, Feng HL, Mao J, Chen JH, Pashley DH, Tay FR


NeoMTA Plus<sup>®</sup>, NeoMTA<sup>®</sup> 2, NeoSEALER™ Flo, NeoPUTTY™

### UNLIKE INERT RESIN AND ZOE MATERIALS, MTA PROVIDES STATE OF THE ART TECHNOLOGY TO PROMOTE BIOACTIVITY AND SUPPORT HEALING

- After placement calcium and hydroxide ions are released from the MTA, promoting hydroxyapatite (HA) formation on the MTA surfaces.
- When HA coats the surface, it hides the underlying MTA to minimize foreign body reactions and support healing responses of the pulpal or periapical tissue.



Calcium phosphate precipitated crystals scattered on the hydrated tricalcium silicate cement surface<sup>4</sup>.



High magnification image of the calcium phosphate crystals<sup>4</sup>.